AMP-Activated Protein Kinase (AMPK) Mediates Nutrient Regulation of Thioredoxin-Interacting Protein (TXNIP) in Pancreatic Beta-Cells by Shaked, Maayan et al.
AMP-Activated Protein Kinase (AMPK) Mediates Nutrient
Regulation of Thioredoxin-Interacting Protein (TXNIP) in
Pancreatic Beta-Cells
Maayan Shaked
., Mali Ketzinel-Gilad
., Erol Cerasi, Nurit Kaiser, Gil Leibowitz*
Endocrinology and Metabolism Service, Department of Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel
Abstract
Thioredoxin-interacting protein (TXNIP) regulates critical biological processes including inflammation, stress and apoptosis.
TXNIP is upregulated by glucose and is a critical mediator of hyperglycemia-induced beta-cell apoptosis in diabetes. In
contrast, the saturated long-chain fatty acid palmitate, although toxic to the beta-cell, inhibits TXNIP expression. The
mechanisms involved in the opposing effects of glucose and fatty acids on TXNIP expression are unknown. We found that
both palmitate and oleate inhibited TXNIP in a rat beta-cell line and islets. Palmitate inhibition of TXNIP was independent of
fatty acid beta-oxidation or esterification. AMP-activated protein kinase (AMPK) has an important role in cellular energy
sensing and control of metabolic homeostasis; therefore we investigated its involvement in nutrient regulation of TXNIP. As
expected, glucose inhibited whereas palmitate stimulated AMPK. Pharmacologic activators of AMPK mimicked fatty acids by
inhibiting TXNIP. AMPK knockdown increased TXNIP expression in presence of high glucose with and without palmitate,
indicating that nutrient (glucose and fatty acids) effects on TXNIP are mediated in part via modulation of AMPK activity.
TXNIP is transcriptionally regulated by carbohydrate response element-binding protein (ChREBP). Palmitate inhibited
glucose-stimulated ChREBP nuclear entry and recruitment to the Txnip promoter, thereby inhibiting Txnip transcription. We
conclude that AMPK is an important regulator of Txnip transcription via modulation of ChREBP activity. The divergent
effects of glucose and fatty acids on TXNIP expression result in part from their opposing effects on AMPK activity. In light of
the important role of TXNIP in beta-cell apoptosis, its inhibition by fatty acids can be regarded as an adaptive/protective
response to glucolipotoxicity. The finding that AMPK mediates nutrient regulation of TXNIP may have important
implications for the pathophysiology and treatment of diabetes.
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Introduction
Beta-cell dysfunction is the hallmark of type 2 diabetes [1]. Little
is known about the mechanisms that initiate type 2 diabetes;
however, hyperglycemia and elevated free fatty acids (FFA) play
an important role in the progression of beta-cell dysfunction in
diabetes, a process called glucolipotoxicity [2]. The mechanism of
beta-cell glucolipotoxicity, while not entirely clear, is believed to
involve oxidative and ER stress [3,4]. Hyperglycemia and FFA act
in concert to amplify the stress response in beta-cells, resulting in
beta-cell dysfunction and apoptosis. However, glucose and FFA
differ in their regulation of the various stress pathways. As an
example, glucose-induced beta-cell apoptosis results mainly from
oxidative stress with stimulation of the intrinsic mitochondrial
death pathway, whereas ER stress plays a central role in FFA-
induced beta-cell apoptosis [3,5]. The divergent effects of glucose
and FFA on oxidative stress could result from differential re-
gulation of the thioredoxin system [6].
Thioredoxin (TRX) is a ubiquitous oxidoreductase, which is
highly expressed in pancreatic b-cells [7]. TRX partners with
thioredoxin reductase and thioredoxin peroxidase to reduce
oxidized proteins and scavenge free radicals [8]. Thioredoxin-
interacting protein (TXNIP), a member of the arrestin family,
binds to the redox-active cysteine residues of TRX and inhibits
its oxidoreductase activity, thus functioning as an endogenous
inhibitor of TRX [9]. Of relevance to the fate of beta-cells in
diabetes, TXNIP expression is robustly induced by glucose in
islets [10,11,12]. Glucose regulates TXNIP by increasing the
binding of the carbohydrate response element-binding protein
(ChREBP) to the Txnip promoter, with recruitment of P300
and histone H4 acetylation, thereby stimulating Txnip tran-
scription [11]. Islets from TXNIP mutant mice, and beta-cells in
which TXNIP was knocked-down, are protected from glucose-
induced apoptosis [6,10,12]. Moreover, TXNIP deficiency was
shown to prevent beta-cell apoptosis and hyperglycemia
in rodent models of type 2 diabetes [13]. Thus, TXNIP is
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d e a t hi nd i a b e t e s .
Contrasting the glucose stimulation of TXNIP, the saturated
long-chain fatty acid palmitate, which is a strong inducer of beta-
cell apoptosis, inhibits TXNIP expression [6]; however, the
mechanisms involved are largely unknown. AMPK is an im-
portant nutrient sensor regulating FFA metabolism in various
tissues including pancreatic beta-cells [14,15]. Furthermore, it was
shown to modulate the activity of various proteins and trans-
cription factors through phosphorylation [16]. In light of the
central role of ChREBP in the regulation of TXNIP and of
AMPK in lipid sensing and metabolism [14], we investigated
whether AMPK and ChREBP are involved in FFA inhibition of
TXNIP in beta-cells.
Methods
Islet isolation and INS-1E beta-cell line culture
Islets were isolated from Wistar rats by collagenase diges-
tion (Collagenase P; Roche Diagnostics GmbH, Mannheim,
Germany), as described [17]. The islets were used after repeated
washes with Hanks’ balanced salt solution, and incubated
overnight in RPMI 1640 medium (Biological Industries,
Beit-Haemek, Israel) containing 5.5 mmol/l glucose with 10%
fetal bovine serum, 100 U/ml penicillin, 100 mcg/ml strepto-
mycin, and 2 mmol/l L-glutamine (Biological Industries). They
were then taken for further incubations as described in
Experimental protocols. Animal use was approved by the Institutional
Animal Care and Use Committee of the Hebrew University and
the Hadassah Medical Organization (approval number: MD-08-
11428-4).
The rat insulinoma cell line INS-1E (kindly provided by
Dr. Walker, The Weizmann Institute of Science, Rehovot, Israel)
was used to study the mechanisms of nutrient regulation of
TXNIP in beta-cells. INS-1E beta-cells were grown in RPMI 1640
medium containing different glucose concentrations as indicated,
and supplemented with 10% fetal bovine serum, 100 U/ml
penicillin, 100 mcg/ml streptomycin, 1 mmol/l sodium pyruvate,
2 mmol/l L-glutamine, 10 mmol/l HEPES and 0.05 mmol/l
2-mercaptoethanol.
Figure 1. Palmitate effects on beta-cell apoptosis and TXNIP expression in INS-1E beta-cells. (A–C) INS-1E cells were incubated for 16 h
with different concentrations of palmitate at 11.1 (G11.1) and 22.2 (G22.2) mmol/l glucose, as indicated. (A) Beta-cell apoptosis was analyzed using
the Cell Death Detection ELISA
PLUS kit (Roche Diagnostics, Mannheim, Germany), as described in the Experimental procedures. (B, C) Concentration-
dependent inhibition of TXNIP analyzed by Western blot. (D, E) Time-course of palmitate inhibition of TXNIP. INS-1E cells were incubated at 11.1 or
22.2 mmol/l glucose alone or with 0.5 mmol/l palmitate for the indicated time. TXNIP protein level was assessed by Western blot. Representative gels
showing the expression of TXNIP (B, D), and quantification of TXNIP expression normalized to GAPDH (C, E) are presented. Results are expressed as
fold of TXNIP expression at 11.1 mmol/l glucose (G11.1) in the absence of palmitate (n=3). (F) Palmitate effect on Txnip mRNA. INS-1E cells were
incubated in medium containing 11.1 or 22.2 mmol/l glucose with and without 0.5 mmol/l palmitate for 16 h. Txnip mRNA levels were analyzed by
qPCR and corrected for the 18S rRNA, which served as an internal control. Results are normalized to Txnip mRNA levels at G22.2 without palmitate
(n=10). (G) Palmitate effect on Txnip gene transcription. Transcriptional activity was analyzed following transient transfection with a reporter
construct encoding the human Txnip promoter region 1777 bp upstream of the ATG start codon, followed by 16 h incubation at 5.5, 11.1 and
22.2 mmol/l glucose. Results are normalized to transcriptional activity at G5.5 without palmitate. Data are expressed as means 6 SEM (n=4).
*p ,0.05, ** p,0.01, ‘ p,0.001 for the difference between the indicated groups (F, G) and untreated cells at the same glucose concentration (A, C,
E), or between palmitate-treated and the paired untreated cells at the same glucose concentration (C, E, F, G).
doi:10.1371/journal.pone.0028804.g001
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INS-1E cells and rat islets were incubated in RPMI medium
with 0.55% (w/v) BSA with or without palmitate at various
glucose concentrations for different periods of time, as indicated in
the Figure legends. The palmitate-BSA solution was prepared as
described [18]. Briefly, the sodium salt of palmitic acid was
dissolved at a concentration of 10 mmol/l in 11% fatty acid- and
endotoxin-free BSA in a shaking water bath at 37uC for 16 h. The
pH was adjusted to 7.4 with 1 N NaOH, and the solution filtered
through a 0.2 micrometer filter and stored at 220uC. Different
dilutions of the palmitate-BSA solution were used as indicated in
the Figure legends. In some experiments, INS-1E cells were
treated with oleate, or non-metabolizable palmitic acid MEDICA
analogs [19] (kindly provided by Dr. Rachel Hertz, the Hebrew
University, Jerusalem, Israel). The effect of AMPK activation on
TXNIP expression was studied by treating INS-1E cells and islets
with metformin or aminoimidazole-carboxamide ribonucleotide
(AICAR). All reagents were purchased from Sigma (Rehovot,
Israel).
AMPKalpha1 and AMPKalpha2 knockdown
Knockdown of AMPK isoforms was performed by transient
transfection of 50 nmol/l small interfering RNA (siRNA) oligos
for AMPKalpha1 and AMPKalpha2 (Dharmacon L-091373 and
L-100623, Lafayette, CO) to INS-1E cells, plated in 12-well plates
and grown overnight to approximately 50–70% confluence.
Scrambled siRNA oligos (AllStars Negative Control, Qiagen,
Basel, Switzerland) served as negative control. Transfection was
performed in serum-free RPMI medium using JetPRIME
(PolyPlus transfection, Illkirch, France) according to the manufac-
turer’s instructions. Twenty-four hours after transfection the
medium was replaced with the regular culture medium, and after
additional 48 h the cells were incubated overnight at different
glucose concentrations with and without palmitate or metformin,
followed by extraction and analysis for the expression of AMPK
isoforms and TXNIP.
Quantitative real-time RT-PCR
RNA was extracted from INS-1E cells using Bio Tri RNA
(Biolab, Jerusalem, Israel). Samples of 1 mcg total RNA were
reverse-transcribed using Moloney murine leukemia virus reverse
transcriptase (Promega, Madison, WI). Quantitative real time RT-
PCR (qPCR) for TXNIP, AMPKalpha1 and AMPKalpha2 was
performed with ABI PRISM 7900HT Sequence Detection
System using the TaqMan Gene Expression Assay (Applied
Biosystems, Foster City, CA). All samples were analyzed in
Figure 2. Effects of oleate and 2-deoxyglucose (2-DG) on TXNIP expression in INS-1E beta-cells. (A, B) Oleate concentration-dependent
inhibition of TXNIP. INS-1E cells were incubated for 16 h with different concentrations of oleate at 11.1 (G11.1) or 22.2 (G22.2) mmol/l glucose, as
indicated. TXNIP protein level was assessed by Western blot. A representative gel showing the expression of TXNIP, and quantification of TXNIP
expression normalized to GAPDH are presented. Results are given as fold of TXNIP expression at 11.1 or 22.2 mmol/l glucose (G11.1 or G22.2) in the
absence of oleate (B, upper and lower panels, respectively), and expressed as means 6 SEM of 7 individual experiments. (C, D) Effect of 2-DG on
palmitate inhibition of TXNIP. INS-1E cells were incubated at 5.5 mmol/l glucose with and without 0.5 mmol/l palmitate and 5 mmol/l 2-DG for 4 h. A
representative gel showing the expression of TXNIP (C), and quantification of TXNIP expression normalized to GAPDH (D) are presented (n=7).
*p ,0.05, ** p,0.01, for the difference between the indicated groups (D), and between the indicated groups and untreated cells at the same glucose
concentration (B, D).
doi:10.1371/journal.pone.0028804.g002
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internal control.
Transient and stable Txnip promoter transfection
experiments
INS-1E cells were plated in 24-well plates and grown overnight
to approximately 70% confluence. Cells were cotransfected with a
luciferase reporter construct encoding the human Txnip promoter
region 1777 bp upstream of the ATG start codon (FL) or with its
carbohydrate response element (ChoRE) (D4) [11] (kindly
provided by Dr. Anath Shalev, University of Wisconsin-Madison,
Madison, WI), and with Renilla luciferase reporter plasmid
(Biological Industries). Transfection was performed in serum-free
RPMI using lipofectamine (Invitrogen). Six hours after transfec-
tion the medium was replaced and transcriptional activity assessed
following an overnight incubation in medium containing different
glucose concentrations without and with palmitate or metformin.
In part of the experiments, the effects of different treatments on
Txnip transcription were assessed using a stable reporter cell line:
INS-1E beta-cells were stably transfected with constructs harbor-
ing luciferase under the control of the full-length Txnip promoter
and pcDNA3 plasmid, which contains a neomycin resistance gene.
Stable INS-1E beta-cell lines were generated by antibiotic
selection following transfection; luciferase activity was determined
using the luciferase assay kit (Promega).
Chromatin immunoprecipitation (ChIP)
ChIP asssays were performed using a ChIP assay kit (Simple-
ChIP
TM, Cell Signaling, Boston, MA) according to the manufac-
turer’s instructions. Lysates were prepared from 10
8 cells per each
treatment. Immunoprecipitation was performed overnight at 4uC
with 4 mcg of anti-ChREBP antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) or with Normal Rabbit-IgG antibody, used as a
negative control (SimpleChIP
TM, Cell Signaling). The purified
DNA fragments were quantified by real-time PCR using the Power
SYBRHGreen system (Applied Biosystems) with primers corre-
sponding to the Txnip ChoRE: sense, 59-AAGGACCAAGTAGC-
CAATGGG; antisense, 59- GTGCTGGCCCGGAGG.
Figure 3. Non-metabolizable fatty acids and palmitate modulate AMPK activity and TXNIP expression in INS-1E beta-cells. (A) Effects
of non-metabolizable MEDICA analogs on AMPK activity and TXNIP expression. MEDICA analogs were generated by substitution of alpha, omega-
dicarboxylic acids of C16 chain length. INS-1E cells were incubated for 16 h at 11.1 (G11.1) and 22.2 (G22.2) mmol/l glucose with and without beta,
beta’- or alpha, alpha’-tetramethyl-hexadecanedioic acid (M16alpha/alpha and M16beta/beta, respectively). AMPK activity was assessed by measuring
phosphorylated acetyl CoA carboxylase (pACC). pACC and TXNIP protein levels were analyzed by Western blot. Quantification of TXNIP expression
normalized to GAPDH (B) and ACC phosphorylation normalized to ACC (C) presented. (n=3). (D) Effect of palmitate treatment on AMPK activity. INS-
1E cells were incubated at different glucose concentrations without and with 0.5 mmol/l palmitate in KRBH buffer for 1 h. A representative gel of
phospho- and total ACC and GAPDH is shown, and quantification of ACC phosphorylation presented. Results are expressed as fold of untreated cells
at 3.3 mmol/l glucose (n=10). * p,0.05, ** p,0.01, ‘ p,0.001 for the difference between MEDICA analog-treated cells and controls at the same
glucose concentration (B, C), between untreated cells at different glucose concentrations and controls at 3.3 mmol/l glucose (G3.3) (D), and between
palmitate-treated cells and the paired controls at the same glucose concentration (D).
doi:10.1371/journal.pone.0028804.g003
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INS-1E cells were plated on glass cover-slips pre-treated with
poly-D-lysine (10 mcg/ml) (Sigma). The cells were treated for 4 h
with 3.3 or 22.2 mmol/l glucose, with or without 0.5 mmol/l
palmitate or 1 mmol/l metformin, and fixed in 4% paraformal-
dehyde (Biolab). Following permeabilization with 0.2% Triton X-
100 (Sigma), the cells were incubated with goat antibody against
human ChREBP (1:50) (Santa Cruz Biotechnology); the secondary
antibody for detection was rhodamine-conjugated donkey anti-
goat antibody (1:200) (Jackson ImmunoResearch Laboratories,
West Grove, PA). Mounting medium containing DAPI (Vector
Laboratories, Inc., Burlingame, CA) was used for nuclear
counterstaining and the specimens were visualized with a Nikon
E600 fluorescent microscope.
Western blot analysis
Protein expression in whole cell and nuclear extracts was
studied by Western blot using antibodies against TXNIP (MBL
International Co, Woburn, MA), total AMPK, total and
phosphorylated (Ser 79) acetyl CoA carboxylase (ACC) (Cell
Signaling Technology, Beverley, MA), AMPKalpha1 and alpha2
(Upstate Biotechnology, Lake Placid, NY), ChREBP, Lamin B and
GAPDH (Santa Cruz Biotechnology). Immunoreactive bands
were visualized by chemiluminescence with ECL-Plus (Biological
Industries). X-ray film densitometry was used for quantification
(ImageMaster VDS-CL, Amersham Pharmacia Biotech, Buck-
inghamshire, UK). Immunoblots were scanned by ImageMaster
and signals quantified using TINA Software.
Apoptosis ELISA assay
INS-1E cells plated in 96-well plates were grown in RPMI 1640
containing 11.1 mmol/l glucose until reaching 70% confluence.
The cells were then treated with 0.55% (w/v) BSA without or with
increasing concentrations of palmitate at 11.1 and 22.2 mmol/l
glucose for 16 h. They were then lysed and oligonucleosomes in
the cytosol, indicative of apoptosis-induced DNA degradation,
quantified using the Cell Death Detection ELISA
PLUS kit
(Roche Diagnostics, Mannheim, Germany) according to the
manufacturer’s instructions.
Data presentation and statistical analysis
Data shown are means 6 SEM. Statistical significance of
differences between groups was determined by one-way ANOVA
followed by Newman-Keuls test using the InStat statistical
program from GraphPad Software, Inc. (San Diego, CA). A
paired-sample t test was used when the difference between a
reference (taken as 100%) and test was analyzed. A P value of less
than 0.05 was considered significant.
Figure 4. Effect of AMPK activators on TXNIP expression in INS-1E beta-cells. (A, B) Metformin concentration-dependent inhibition of
TXNIP. INS-1E cells were incubated for 16 h with different concentrations of metformin at 11.1 (G11.1) or 22.2 (G22.2) mmol/l glucose. TXNIP protein
level was assessed by Western blot. A representative gel for TXNIP (A) and quantification of TXNIP expression normalized to GAPDH (B) are presented.
Results are expressed as fold of TXNIP expression at 11.1 mmol/l glucose in the absence of metformin (n=3). (C, D) Metformin effect on Txnip mRNA
and gene transcription. INS-1E cells were incubated in medium containing 11.1 or 22.2 mmol/l glucose with and without 1 mmol/l metformin for
16 h. (C) Txnip mRNA levels were analyzed by qPCR and corrected for the 18S rRNA, which served as an internal control (n=5). (D) Transcriptional
activity was analyzed in INS-1E cells that were stably transfected with a reporter construct encoding the human Txnip promoter region 1777 bp
upstream of the ATG start codon. The cells were treated at 22.2 mmol/l glucose for 16 h with different concentrations of metformin (n=3). (E, F)
AICAR effect on TXNIP protein level. INS-1E cells were incubated in medium containing 11.1 or 22.2 mmol/l glucose with and without 1 mmol/l AICAR
for 16 h. A representative blot (E) and quantification of TXNIP expression normalized to GAPDH (F), are shown. Results are expressed as means 6 SEM
(n=3). * p,0.05, ** p,0.01, ‘ p,0.001 for the difference between the indicated groups and untreated cells at the same glucose concentration (B, D)
or between metformin treatment (C) or AICAR treatment (F) groups and the paired control group at the same glucose concentration.
doi:10.1371/journal.pone.0028804.g004
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Fatty acids inhibit TXNIP expression
In INS-1E beta-cells palmitate increased beta-cell apoptosis at
both 11.1 and 22.2 mmol/l glucose (Figure 1A). Palmitate
stimulation of apoptosis was inversely related to its effect on
TXNIP expression, which was decreased by palmitate in a
concentration-related manner (Figure 1B, C). A time-course study
showed that the inhibition of TXNIP occurred already after a 1-h
incubation and progressed over time (up to 16 h) (Figure 1D, E).
At both 11.1 and 22.2 mmol/l glucose, 0.5 mmol/l palmitate
induced 50–70% decrease in TXNIP mRNA expression
(Figure 1F), promoter activity (Figure 1G) and protein level
(Figure 1B–E), indicating that palmitate inhibits TXNIP at the
level of transcription. The monounsaturated long-chain fatty acid
oleate, like palmitate, inhibited TXNIP expression at 11.1 and
22.2 mmol/l glucose (Figure 2A, B). There was substantial inter-
experimental variation in TXNIP expression at 22.2 mmol/l
compared to 11.1 mmol/l glucose. Normalization of TXNIP
protein level to that at 22.2 mmol/l glucose showed that oleate
inhibition of TXNIP at high glucose was significant and similar to
that induced by palmitate (Figure 2B).
It was recently suggested that TXNIP expression is regulated by
the glycolytic flux via modulation of the glucose-6 phosphate (G6P)
level, which transmits the glucose signal [20]. 2-Deoxyglucose
(2-DG) undergoes phosphorylation to 2-DG-6-phosphate without
further metabolism, and thus can mimic the effect of G6P without
the contribution of other glycolytic intermediates. Consistent with
the hypothesis that early glycolytic intermediates regulate TXNIP,
we found that 2-DG stimulated TXNIP like glucose (Figure 2C–
D). Notably, palmitate markedly inhibited 2-DG stimulation of
TXNIP, indicating that FFA inhibition of TXNIP expression is
independent of glycolysis (Figure 2C–D).
The role of fatty acid beta-oxidation and/or esterification in
FFA regulation of TXNIP was examined using non-metabolizable
MEDICA analogs, which are neither oxidized nor esterified.
These analogs were generated by substitution of alpha, omega-
dicarboxylic acids of C16 chain length [19]. Beta, beta’- and
alpha, alpha’-tetramethyl-hexadecanedioic acid (M16) effectively
decreased TXNIP expression (Figure 3A–B), indicating that the
inhibition of TXNIP by FFA is independent of esterification
products or fatty acid oxidation.
cAMP is a potent inhibitor of TXNIP, in part through
stimulation of protein kinase A (PKA) [21]. We further studied
whether the cAMP-PKA pathway is involved in palmitate
inhibition of TXNIP. INS-1E cells were treated with 3-isobutyl-
1-methylxanthine (IBMX) or palmitate without and with the PKA
inhibitor H89. H89 partially prevented IBMX, but not palmitate
inhibition of TXNIP (Supplementary Figure S1), suggesting that
FFA regulation of TXNIP is not mediated via cAMP-PKA.
Association between fatty acid stimulation of AMPK and
inhibition of TXNIP
In agreement with previous studies [22,23,24,25], high glucose
decreased the AMPK activity in beta-cells, evidenced by decreased
phosphorylation of the AMPK substrate ACC, whereas palmitate
acutely stimulated AMPK activity (Figure 3D). Non-metabolizable
MEDICA analogs are potent stimulators of AMPK (Figure 3A, C).
Consistent with the hypothesis that AMPK regulates TXNIP, the
degree of AMPK activation by the analogs correlated with their
extent of TXNIP inhibition. To further study the role of AMPK in
the regulation of TXNIP, we used two pharmacological activators
of AMPK, metformin and AICAR. In INS-1E cells, metformin
inhibited TXNIP transcription, gene expression and protein level
in a concentration-related manner (Figure 4). Similarly, the
AMPK activator AICAR also decreased the TXNIP protein level
(Figure 4E, F). The inhibition of TXNIP by palmitate and
metformin was confirmed in primary rat islets (Figure 5).
Regulation of TXNIP by AMPKalpha
The catalytic activity of AMPK resides in the alpha subunit
[15], which occurs as two isoforms, alpha1 and alpha2. We studied
the respective role of these isoforms in nutrient regulation of
TXNIP. First, we analyzed the effects of different glucose
concentrations and palmitate on the expression of AMPKalpha1
and alpha2 in beta-cells. We found that total AMPK levels and the
relative expression of AMPKalpha1 and alpha2 were not affected
by the glucose concentration or palmitate treatment (Supplemen-
tary Figure S2). Next, we performed knockdown of the
AMPKalpha isoforms and studied TXNIP expression. Knock-
down of AMPKalpha1 and alpha2 increased Txnip mRNA and
protein level in INS-1E cells incubated at 22.2 mmol/l glucose
without and with palmitate (Figure 6). Knockdown of AMPKalpha
prevented palmitate inhibition of Txnip mRNA with a smaller
effect on protein level. Notably, palmitate did not decrease
significantly TXNIP protein level in INS-1E cells in which
AMPKalpha1 and alpha2 were silenced together. Collectively,
these findings suggest that nutrients (glucose and fatty acids) affect
TXNIP in part via modulation of AMPK activity; however,
additional mechanisms are probably involved in the regulation of
Figure 5. Palmitate and metformin effects on TXNIP protein
levels in rat islets. Rat islets were allowed to recover overnight at
RPMI medium containing at 5.5 mmol/l glucose and then incubated in
medium containing 3.3 (G3.3) or 27.8 (G27.8) mmol/l glucose with and
without 0.5 mmol/l palmitate (Palm.) or 1 mmol/l metformin (Met.) for
16 h. TXNIP and GAPDH protein levels were assessed by Western blot. A
representative gel showing the expression of TXNIP and GAPDH, and
quantification of TXNIP expression normalized to GAPDH are presented.
Results are expressed as fold of TXNIP expression at 27.8 mmol/l
glucose and shown as means 6 SEM of 3 individual experiments, each
performed on islets pooled from three animals. ‘ p,0.001 for the
differences between the indicated groups or between these islets at
27.8 mmol/l glucose and control islets at 3.3 mmol/l glucose.
doi:10.1371/journal.pone.0028804.g005
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knockdown did not affect TXNIP mRNA and protein levels
(Figure 6), indicating that AMPK inactivation is not sufficient for
induction of TXNIP at low glucose. Furthermore, while 2-DG
inhibits glycolysis, resulting in increased AMPK activity (Supple-
mentary Figure S3), it still increased TXNIP (Figure 2C–D).
Collectively, these findings suggest that the interplay between
glycolytic substrate availability and AMPK activity determines the
level of TXNIP expression.
AMPK regulation of glucose-stimulated ChREBP activity
ChREBP plays a central role in the transcriptional regulation of
TXNIP in beta-cells [11]. We studied the effects of palmitate and
metformin on ChREBP nuclear localization by immunostaining
and Western blot analysis (Figure 7), and on chromatin binding to
the Txnip promoter by ChIP assay (Figure 8A). In INS-1E cells
incubated at 3.3 mmol/l glucose, ChREBP was mostly localized in
the cytoplasm. At 22.2 mmol/l glucose, the nuclear localization of
ChREBP was rapidly increased (within 30 min of glucose
stimulation; not shown), and remained high for at least 4 h
(Figure 7A). ChREBP was found in the nuclei of ,80% of the
cells, although cytosolic expression was still present. The level of
nuclear import of ChREBP varied between cells. Notably,
treatment with palmitate or metformin resulted in nuclear
exclusion of ChREBP, mimicking the effect of low glucose.
Chromatin immunoprecipitation (ChIP) assay (Figure 8A)
showed that high glucose (22.2 mmol/l) increased ChREBP
recruitment to the Txnip promoter by 4.5-fold, and that palmitate
and metformin decreased ChREBP binding by 65% and 90%,
respectively. Glucose-induced Txnip transcription depends on a
400 bp proximal region of the Txnip promoter, which contains a
conserved ChoRE consisting of 2 non-palindromic E-boxes [26].
Transfection experiments using a luciferase reporter construct dri-
ven by the ChoRE showed, as expected, that high (22.2 mmol/l)
glucose increased ChoRE-Txnip promoter activity by ,5-fold
relative to treatment with low (5.5 mmol/l) glucose; palmitate and
metformin reduced the glucose stimulation of the ChoRE-Txnip
promoter (Figure 8B).
Taken together, our findings show that fatty acids activate
AMPK in beta-cells exposed to high glucose. Furthermore, fatty
acids attenuate the glucose stimulation of ChREBP nuclear entry
and its recruitment to the Txnip promoter, thereby inhibiting
Txnip transcription. AMPK mediates the inhibition of TXNIP by
fatty acids and is involved in TXNIP regulation by glucose.
Discussion
In beta-cells, glucose and FFA have opposing effects on TXNIP
expression. Glucose is the most potent physiological inducer of
TXNIP [10,11,26], whereas FFA (palmitate, oleate and MEDICA
analogs) function as TXNIP repressors [6]. We found that FFA
Figure 6. Effect of AMPKalpha isoform knockdown on TXNIP expression in INS-1E beta-cells. INS-1E cells were transfected with siRNA
oligos for AMPKalpha1 (black bars), AMPKalpha2 (grey bars) or both (diagonal lines) or with control scrambled (Scr) RNA oligos (white bars) as
described in the Methods. The cells were then incubated for 16 h at 3.3 (G3.3) and 22.2 mmol/l (G22.2) glucose without and with 0.5 mmol/l
palmitate (P). (A) Txnip mRNA levels were analyzed by qPCR and corrected for 18S rRNA, which served as an internal control. Results are normalized to
TXNIP mRNA levels at G22.2 (n=8). (B) TXNIP, AMPKalpha1, AMPKalpha2 and GAPDH protein levels were assessed by Western blot. A representative
gel and quantification of TXNIP expression normalized to GAPDH are presented. Results are expressed as fold of TXNIP expression in control cells at
22.2 mmol/l glucose and shown as means 6 SEM of 11 individual experiments. * p,0.05, ** p,0.01 for the difference between the indicated groups
or between similarly treated AMPKalpha knockdown cells and their controls; NS – non significant.
doi:10.1371/journal.pone.0028804.g006
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being rapid in onset, progressive over time and qualitatively
similar using both saturated (palmitate) and unsaturated (oleate)
fatty acids. Consistent with a previous study [20], we found that
increasing the level of hexose-6-phosphate by administration of 2-
DG increased TXNIP. Importantly, also in the presence of 2-DG,
palmitate inhibited TXNIP, indicating that the inhibitory effect of
fatty acids is not due to diminution of glycolytic intermediates
which regulate TXNIP, since 2DG-6P can not be metabolized
further in the beta-cell. Moreover, non-metabolizable fatty acids
also decreased TXNIP; thus fatty acid metabolism is not a
prerequisite for the inhibition of TXNIP by FFA. The finding that
palmitate inhibition of TXNIP was rapid and independent of fatty
acid metabolism may suggest that this effect is mediated via G-
protein coupled receptors (GPCR). Long-chain fatty acids and
their derivatives may bind to GPCR, which mediate their effects
on important biological processes in the beta-cell including insulin
secretion [27]. Future studies will clarify whether GPCR mediate
FFA inhibition of TXNIP and which receptor is involved in this
process.
Our findings strongly suggest that nutrient regulation of TXNIP
is mediated via AMPKalpha. At high glucose, AMPK activity is
decreased; however this inhibition is incomplete. The residual
activity of AMPK in hyperglycemia restrains TXNIP expression,
as its knockdown augmented glucose stimulation of TXNIP. The
observation that the AMPK activators metformin and AICAR
markedly decreased TXNIP expression at high glucose further
supports the role of AMPK in the regulation of TXNIP under
conditions of hyperglycemia. Contrasting the effect of glucose,
FFA stimulated AMPK and decreased TXNIP expression.
Importantly, AMPKalpha silencing prevented the inhibition of
TXNIP by fatty acid, thus stressing the central mediator role of
AMPKalpha in this regulatory loop. AMPK is not the exclusive
factor regulating TXNIP in response to changes in nutrient
availability. This claim is based on the following observations: 1.
AMPKalpha knockdown failed to induce TXNIP at low glucose;
2. 2-DG stimulates TXNIP, while inhibiting glycolysis with
simultaneous activation of AMPK. Thus, the regulation of TXNIP
by nutrients is complex and influenced by their impact on
glycolytic substrate availability and on signaling pathways,
including AMPK.
Gene expression analysis and transfection experiments clearly
showed that FFA inhibited TXNIP at the level of transcription.
The transcription factor ChREBP has been shown recently to play
a central role in glucose stimulation of TXNIP [11]. Consistent
with this, we found that glucose rapidly increased the nuclear
localization of ChREBP and its recruitment to the Txnip
promoter. Uyeda and Repa [28] showed that ChREBP activity
Figure 7. Modulation of ChREBP nuclear localization by glucose, palmitate and metformin. (A) INS-1E cells were plated on poly-D-lysine
coated glass coverslips, and treated for 4 h with 3.3 (G3.3) or 22.2 (G22.2) mmol/l glucose, without or with 0.5 mmol/l palmitate or 1 mmol/l
metformin. ChREBP localization was analyzed by immunofluorescence using goat antibody against human ChREBP; the secondary antibody was
conjugated with rhodamine (red). Dapi was used for nuclear counterstaining (blue). Arrows denote cells with nuclear localization of ChREBP; scale bar
50 micrometer. (B) The percentage of cells showing nuclear localization of ChREBP under the different experimental conditions is shown. A minimum
of 550 cells were counted. (C) ChREBP protein level was analyzed by Western blot on nuclear and cytosolic extracts of INS-1E cells treated at 5.5 (G5.5,
white columns) and 22.2 (G22.2) mmol/l glucose in the absence (black columns) and with 0.5 mmol/l palmitate (Pal., diagonal columns) for 1 h. A
representative blot is shown; the quantification of the nuclear and cytosolic ChREBP normalized to Lamin B and GAPDH, respectively, and the
nuclear/cytosol ratios of ChREBP are also shown. Results are expressed as means 6 SEM of 6 independent experiments. ** p,0.01, ‘ p,0.001 for the
difference between the indicated groups and untreated cells at G22.2.
doi:10.1371/journal.pone.0028804.g007
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which affect its subcellular localization and DNA binding.
According to this model, phosphorylation of ChREBP residues
Ser-196, Ser-626 and Thr-666 at low glucose restricts it to the
cytoplasm, thereby inhibiting its activity [29]. Glucose activates
the phosphatase PP2A leading to dephosphorylation of ChREBP
at these sites, thus promoting its nuclear localization and DNA
binding [30]. This model, however, has been challenged by others
[31,32,33,34]. We found that palmitate reduced ChREBP nuclear
localization in response to glucose. The precise mechanism is
currently unknown; yet, this is expected to inhibit ChREBP
activity. Indeed, the decrease of ChREBP nuclear localization was
accompanied by inhibition of ChREBP-stimulated Txnip tran-
scription. Moreover, metformin decreased both ChREBP nuclear
localization and its chromatin binding to the Txnip promoter. Yet,
AMPK may affect ChREBP chromatin binding directly, indepen-
dent of its nuclear localization. Consistent with this hypothesis,
high-fat feeding was previously shown to increase liver AMPK
activity, leading to ChREBP phosphorylation and consequently to
inhibition of its DNA binding, without affecting its nuclear
localization [35]. It is noteworthy that cAMP also was shown to
repress ChREBP activity through PKA-mediated phosphorylation
adjacent to the nuclear localization signal of the molecule [29,36].
This promotes interactions with 14-3-3 proteins and thus
sequesters ChREBP in the cytosol [37]. Others and we have
previously shown that GLP-1 and the phosphodiesterase inhibitor
IBMX, which raise cAMP levels, inhibited TXNIP expression in
beta-cells [12,38]. Taken together, these findings suggest that
AMPK- and cAMP/PKA-mediated ChREBP phosphorylations
provide an important mechanism for the regulation of TXNIP
expression. Microinjection of antibodies against AMPKalpha2
increased proinsulin and L-type pyruvate kinase (L-PK) gene
transcription in beta-cells, mimicking the glucose effects [39]. The
finding that inhibition of AMPKalpha enhanced the expression of
bona fide ChREBP targets, such as L-PK [28] and TXNIP (this
study), suggests that AMPKalpha-ChREBP orchestrates a genetic
network implicated in nutrient metabolism and oxidative stress.
TXNIP inhibits glucose uptake in different tissues [40,41], thus
suppression of TXNIP by FFA may promote glucose uptake,
thereby ensuring adequate glycolytic intermediates for effective
fatty acid metabolism. However, in contrast to muscle and fat,
glucose uptake in the beta-cell is mediated via glucose transporter 2
(GLUT2), which has a low affinity for glucose, and is thus not a
regulatory step in beta-cell glucose metabolism [42]. Therefore
this hypothesis seems to be less likely. Palmitate is toxic to beta-
cells; the finding that FFA inhibit rather than increase TXNIP
Figure 8. Palmitate and metformin effects on ChREBP recruitment to the Txnip promoter, and on glucose stimulation of the
carbohydrate response element (ChoRE). (A) INS-1E cells were treated at 3.3 (G3.3) and 22.2 (G22.2) mmol/l glucose in the absence and with
0.5 mmol/l palmitate or 1 mmol/l metformin for 6 h. ChREBP recruitment to the Txnip promoter was studied by ChIP assay using anti-ChREBP and
anti-IgG (negative control) antibodies. The ChoRE region of rat Txnip promoter was amplified by quantitative real-time RT-PCR and the percentage of
occupied promoter calculated. Results are means 6 SEM of 4 independent experiments. (B) Transcriptional activity was analyzed following transient
transfection with a reporter construct encoding the conserved ChoRE binding site in the TXNIP promoter region 400 bp upstream of the ATG start
codon. The transfected cells were then treated at 3.3 and 22.2 mmol/l glucose without and with 0.5 mmol/l palmitate or 1 mmol/l metformin for
16 h. Results are means 6 SEM of 5 independent experiments. * p,0.05, ** p,0.01, ‘ p,0.001 for the difference between the indicated groups or
between G22.2 and G3.3.
doi:10.1371/journal.pone.0028804.g008
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oxidative stress induced by inhibition of the thioredoxin system.
Palmitate stimulation of beta-cell apoptosis paralleled its inhibition
of TXNIP expression (Figure 1). Therefore, palmitate inhibition of
TXNIP may be considered an adaptive defense mechanism in the
face of glucolipotoxicity-induced cellular stress, aimed to reduce its
impact on beta-cell function and survival. It might be expected
that activation of AMPK and consequently inhibition of TXNIP
would improve beta-cell survival. However, the role of AMPK in
beta-cell survival is highly controversial. Several studies showed
that activation of AMPK could lead to beta-cell apoptosis [43,44],
and that AMPK inhibition may protect beta-cells from immune-
mediated death [45]. On the other hand, others showed that nitric
oxide (NO) activated AMPK, which then suppressed apoptotic
signals, allowing the beta-cells to recover from nitrosative stress
[46]. Consistent with this, we found that NO inhibited TXNIP
expression, whereas NOS inhibition increased it [12]. The
conflicting results regarding the role of AMPK in beta-cell survival
could result from the complex regulation of multiple metabolic
and stress pathways by AMPK including, but not limited to,
TXNIP expression. Thus, the impact of AMPK activation on
beta-cell survival seems to vary depending on the metabolic
context and the cellular system used; this may explain the finding
that AMPK activation is not consistently beneficial for beta-cell
survival despite TXNIP inhibition.
In summary, we found that fatty acids are negative regulators of
TXNIP, the effect being mediated via AMPKalpha, leading to
ChREBP inactivation with reduced Txnip transcription. Under
conditions of hyperglycemia, residual AMPKalpha activity
restricts the TXNIP stimulation by glucose. Thus, AMPK plays
a crucial role in the regulation of TXNIP by nutrients. These
findings may have important implications for the development
of novel therapeutic strategies for diabetes based on TXNIP
inhibition.
Supporting Information
Figure S1 cAMP-PKA regulation of TXNIP in INS-1E
beta-cells. INS-1E cells were incubated for 4 h at 22.2 mmol/l
glucose with 0.1 mmol/l 3-isobutyl-1-methylxanthine (IBMX) or
0.5 mmol/l palmitate, without or with the protein kinase A (PKA)
inhibitor H89 (10 micromol/l). Cells treated with H89 were pre-
incubated with the inhibitor for 30 minutes. TXNIP expression
was analyzed by Western blot. A representative experiment and
quantification of TXNIP expression normalized to GAPDH are
shown. Results are expressed as means 6 SEM (n=4). ‘ p,0.001
for the difference between the IBMX treatment group and control
(untreated cells at G22.2), and * p,0.05 for the difference between
the IBMX treatment groups without and with H89; NS- non
significant.
(TIF)
Figure S2 Glucose and palmitate effects on total AMPK
and AMPKalpha isoform protein level (A–B) and gene
expression (C–D). INS-1E cells were incubated at 11.1 or
22.2 mmol/l glucose with and without 0.5 mmol/l palmitate for 3,
6 and 16 h. AMPKalpha1 and AMPKalpha2 protein levels were
analyzed by Western blot (A, B). A representative gel (A) and
quantification of AMPKalpha isoform expression at 16 h nor-
malized to control protein levels at 3.3 mmol/l glucose (B) are
shown. AMPKalpha isoform expression was normalized to
GAPDH. AMPK isoform mRNA levels were analyzed by qPCR
and normalized to mRNA levels at 3.3 mmol/l glucose (G3.3)
(C–D). Results are expressed as means 6 SEM (n=3).
(TIF)
Figure S3 Effects of 2-deoxyglucose (2-DG) on AMPK
activity. INS-1E cells were incubated at 5.5 mmol/l glucose
without and with 5 mmol/l 2-DG for 4 h. AMPK activity was
assessed by measuring phosphorylated acetyl CoA carboxylase
(pACC). A representative gel of phospho- and total ACC and
quantification of 4 independent experiments is shown. Results are
expressed as fold of untreated cells. * p,0.05 for the difference
between the 2-DG treatment group and untreated controls.
(TIF)
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